INNATE PHARMA : R&D update on April 10, 2014 in New York

  • Innate Pharma will update investors and analysts on its pipeline and strategy
  • The Company will present the clinical development plan of IPH2201 NKG2A checkpoint inhibitor, expected to start Phase II in 2014

MARSEILLE, France, March 17, 2014 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Company will host a Research and Development Update on April 10, 2014, in New York, from 8am to 1pm.

At this R&D Update, Innate Pharma's management team will review and discuss with attendees Innate Pharma's pipeline and strategy. The Company will present the clinical development plan for IPH2201, a first-in-class NKG2A checkpoint inhibitor, which Phase II in oncology is expected to start in 2014.

Attendance is by invitation only and subject to room capacity.

The R&D Update will be live webcasted and also available after the event at the following link:

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company conducting research and development of innovative immunotherapy drug candidates for cancer and inflammatory diseases.

The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Three product-candidates resulting from the company's research platform are currently being tested in clinical trials, two of which by partners Bristol-Myers Squibb and Novo Nordisk A/S.

Listed on Euronext-Paris, Innate Pharma is based in Marseilles, France, and had 84 employees as at December 31, 2013.

Learn more about Innate Pharma at

Practical Information about Innate Pharma shares:

ISIN code

Ticker code



This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website ( or on Innate Pharma's website (

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma ATCG Press
Laure-Hélène Mercier

Director, Investor Relations
Marielle Bricman
Phone: +33 (0)4 30 30 30 87 Mob.: +33 (0)6 26 94 18 53

R&D update on April 10, 2014 in New York